137 related articles for article (PubMed ID: 27118107)
1. Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes.
Wolf P; Winhofer Y; Krssak M; Smajis S; Harreiter J; Kosi-Trebotic L; Fürnsinn C; Anderwald CH; Baumgartner-Parzer S; Trattnig S; Luger A; Krebs M
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):387-92. PubMed ID: 27118107
[TBL] [Abstract][Full Text] [Related]
2. Free fatty acid availability is closely related to myocardial lipid storage and cardiac function in hypoglycemia counterregulation.
Winhofer Y; Krššák M; Wolf P; Anderwald CH; Geroldinger A; Heinze G; Baumgartner-Parzer S; Marculescu R; Stulnig T; Wolzt M; Trattnig S; Luger A; Krebs M
Am J Physiol Endocrinol Metab; 2015 Apr; 308(8):E631-40. PubMed ID: 25670825
[TBL] [Abstract][Full Text] [Related]
3. Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.
Chen WJY; Diamant M; de Boer K; Harms HJ; Robbers LFHJ; van Rossum AC; Kramer MHH; Lammertsma AA; Knaapen P
Cardiovasc Diabetol; 2017 May; 16(1):67. PubMed ID: 28526033
[TBL] [Abstract][Full Text] [Related]
4. Effects of acute and one-week fatty acid lowering on cardiac function and insulin sensitivity in relation with myocardial and muscle fat and adiponectin levels.
Lehto HR; Pärkkä J; Borra R; Tuunanen H; Lepomaki V; Parkkola R; Knuuti J; Nuutila P; Iozzo P
J Clin Endocrinol Metab; 2012 Sep; 97(9):3277-84. PubMed ID: 22761459
[TBL] [Abstract][Full Text] [Related]
5. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function.
Halbirk M; Nørrelund H; Møller N; Schmitz O; Gøtzsche L; Nielsen R; Nielsen-Kudsk JE; Nielsen SS; Nielsen TT; Eiskjær H; Bøtker HE; Wiggers H
Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1220-5. PubMed ID: 20709866
[TBL] [Abstract][Full Text] [Related]
6. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.
Vestergaard ET; Cichosz SL; Møller N; Jørgensen JOL; Fleischer J
Br J Clin Pharmacol; 2017 Dec; 83(12):2671-2677. PubMed ID: 28736944
[TBL] [Abstract][Full Text] [Related]
7. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure.
Tuunanen H; Engblom E; Naum A; Någren K; Hesse B; Airaksinen KE; Nuutila P; Iozzo P; Ukkonen H; Opie LH; Knuuti J
Circulation; 2006 Nov; 114(20):2130-7. PubMed ID: 17088453
[TBL] [Abstract][Full Text] [Related]
8. Effects of short-term manipulation of serum FFA concentrations on left ventricular energy metabolism and function in patients with heart failure: no association with circulating bio-markers of inflammation.
Salerno A; Fragasso G; Esposito A; Canu T; Lattuada G; Manzoni G; Del Maschio A; Margonato A; De Cobelli F; Perseghin G
Acta Diabetol; 2015 Aug; 52(4):753-61. PubMed ID: 25559351
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of adipose tissue lipolysis increases intramuscular lipid use in type 2 diabetic patients.
van Loon LJ; Manders RJ; Koopman R; Kaastra B; Stegen JH; Gijsen AP; Saris WH; Keizer HA
Diabetologia; 2005 Oct; 48(10):2097-107. PubMed ID: 16096823
[TBL] [Abstract][Full Text] [Related]
10. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
11. Failing heart of patients with type 2 diabetes mellitus can adapt to extreme short-term increases in circulating lipids and does not display features of acute myocardial lipotoxicity.
Nielsen R; Nørrelund H; Kampmann U; Kim WY; Ringgaard S; Schär M; Møller N; Bøtker HE; Wiggers H
Circ Heart Fail; 2013 Jul; 6(4):845-52. PubMed ID: 23733915
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
Makimura H; Stanley TL; Suresh C; De Sousa-Coelho AL; Frontera WR; Syu S; Braun LR; Looby SE; Feldpausch MN; Torriani M; Lee H; Patti ME; Grinspoon SK
J Clin Endocrinol Metab; 2016 Mar; 101(3):1123-33. PubMed ID: 26691888
[TBL] [Abstract][Full Text] [Related]
13. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
Bizino MB; Jazet IM; Westenberg JJM; van Eyk HJ; Paiman EHM; Smit JWA; Lamb HJ
Cardiovasc Diabetol; 2019 Apr; 18(1):55. PubMed ID: 31039778
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.
McCormick LM; Heck PM; Ring LS; Kydd AC; Clarke SJ; Hoole SP; Dutka DP
Cardiovasc Diabetol; 2015 Aug; 14():102. PubMed ID: 26253538
[TBL] [Abstract][Full Text] [Related]
15. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus.
Rijzewijk LJ; van der Meer RW; Smit JW; Diamant M; Bax JJ; Hammer S; Romijn JA; de Roos A; Lamb HJ
J Am Coll Cardiol; 2008 Nov; 52(22):1793-9. PubMed ID: 19022158
[TBL] [Abstract][Full Text] [Related]
16. Plasma adiponectin is modestly decreased during 24-hour insulin infusion but not after inhibition of lipolysis by Acipimox.
Dullaart RP; Riemens SC; Meinardi JR; Wolffenbuttel BH; Sluiter WJ
Scand J Clin Lab Invest; 2005; 65(6):523-31. PubMed ID: 16179286
[TBL] [Abstract][Full Text] [Related]
17. Is cardiorespiratory fitness a determinant of cardiomyopathy in the setting of type 2 diabetes?
Sénéchal M; Ayers CR; Szczepaniak LS; Gore MO; See R; Abdullah SM; Berry JD; McGuire DK; McGavock JM
Diab Vasc Dis Res; 2014 Sep; 11(5):343-51. PubMed ID: 25027700
[TBL] [Abstract][Full Text] [Related]
18. Pericardial- Rather than Intramyocardial Fat Is Independently Associated with Left Ventricular Systolic Heart Function in Metabolically Healthy Humans.
Wolf P; Winhofer Y; Smajis S; Jankovic D; Anderwald CH; Trattnig S; Luger A; Krebs M; Krššák M
PLoS One; 2016; 11(3):e0151301. PubMed ID: 26967641
[TBL] [Abstract][Full Text] [Related]
19. Effects of insulin therapy on myocardial lipid content and cardiac geometry in patients with type-2 diabetes mellitus.
Jankovic D; Winhofer Y; Promintzer-Schifferl M; Wohlschläger-Krenn E; Anderwald CH; Wolf P; Scherer T; Reiter G; Trattnig S; Luger A; Krebs M; Krssak M
PLoS One; 2012; 7(12):e50077. PubMed ID: 23226508
[TBL] [Abstract][Full Text] [Related]
20. Impact of Acipimox Therapy on Free Fatty Acid Efflux and Endothelial Function in the Metabolic Syndrome: A Randomized Trial.
Aday AW; Goldfine AB; Gregory JM; Beckman JA
Obesity (Silver Spring); 2019 Nov; 27(11):1812-1819. PubMed ID: 31571412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
